VOYAGER THERAPEUTICS INC (VYGR)

US92915B1061 - Common Stock

5.91  +0.13 (+2.25%)

After market: 5.91 0 (0%)

Buy % Consensus

88

ChartMill assigns a Buy % Consensus number of 88% to VYGR. The Buy consensus is the weighted average rating of the current analysts ratings.

Analysts have set a mean price target forecast of 18.02. This target is 204.91% above the current price.
VYGR was analyzed by 16 analysts. The buy percentage consensus is at 88. So analysts seem to be very confident about VYGR.
In the previous month the buy percentage consensus was at a similar level.
VYGR was analyzed by 16 analysts, which is quite many. So the average rating should be quite meaningful.

Price Target & Forecast

Price Low Median Mean High 5.9111.1118.3618.0231.50 - 87.99% 210.66% 204.91% 432.99%
Up and Down Grades
Date Firm Action Rating
2024-12-02 Citigroup Initiate Buy
2024-11-14 Canaccord Genuity Maintains Buy -> Buy
2024-11-14 HC Wainwright & Co. Reiterate Buy -> Buy
2024-10-24 HC Wainwright & Co. Reiterate Buy -> Buy
2024-10-16 Leerink Partners Initiate Outperform
2024-08-20 HC Wainwright & Co. Reiterate Buy -> Buy
2024-08-07 Wedbush Maintains Neutral -> Neutral
2024-07-31 HC Wainwright & Co. Reiterate Buy -> Buy
2024-05-16 HC Wainwright & Co. Reiterate Buy -> Buy
2024-05-15 Oppenheimer Maintains Outperform -> Outperform
2024-05-14 Wedbush Maintains Neutral -> Neutral
2024-03-26 Guggenheim Initiate Buy
2024-03-19 HC Wainwright & Co. Initiate Buy
2024-03-07 Citigroup Initiate Buy
2024-01-02 Wells Fargo Upgrade Equal-Weight -> Overweight
2023-08-07 Oppenheimer Reiterate Outperform -> Outperform
2023-05-10 Truist Securities Initiate Buy
2023-05-10 Canaccord Genuity Maintains Buy -> Buy
2023-03-10 Oppenheimer Initiate Outperform
2021-11-03 Chardan Capital Maintains Neutral
2021-10-07 Baird Upgrade Neutral -> Outperform
2021-04-19 Morgan Stanley Maintains Equal-Weight
2021-02-26 Baird Downgrade Outperform -> Neutral